Larry Keefer[1], Shivendra Singh[2]

[1]National Cancer Institute-Frederick, Macromolecular Crystallography Laboratory, 1050 Boyles Street, Bldg. 539, Frederick, Maryland, 21702, USA, [2]University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, Pennsylvania 15213, USA, E-mail：jix@ncifcrf.gov

Glutathione S-transferase (GST) is a superfamily of detoxification enzymes, represented by GSTa, GSTm, GSTp, etc. GSTa is the predominant isoform of GST in human liver, playing important roles for our well being. GSTp is overexpressed in many forms of cancer, thus presenting an opportunity for selective targeting of cancer cells. Our structure-based design of prodrugs intended to release cytotoxic levels of nitric oxide in GSTp-overexpressing cancer cells yielded PABA/NO, which exhibited anticancer activity both in vitro and in vivo with a potency similar to that of cisplatin (Findlay et al. Mol. Pharmacol. 2004, 65, 1070-1079). Here, we present the details on structural modification, molecular modeling, and enzymatic characterization for the design of PABA/NO. The design was efficient because it was on the basis of the reaction mechanism and the structures of related GST isozymes at both the ground state and the transition state. The ground-state structures outlined the shape and property of the substrate-binding site in different isozymes, and the structural information at the transition-state indicated distinct conformations of the Meisenheimer complex of lead compounds in the active site of different isozymes, providing guidance for the modifications of the molecular structure of lead molecules. Two key alterations of a GSTa-selective compound led to the GSTp-selective PABA/NO.

Keywords: structure-based drug design, anticancer prodrug, PABA/NO

P04.15.359

Structure of the LBD of rat VDR in complex with a non-seco-steroidal vitamin D3 analogue YR301

Shinji Kakuda[1], Kazuhisa Okada[1], Hiroshi Eguchi[1], Kazuya Takenouchi[1], Wataru Hakamata[2], Masaaki Kurihara[2], Midori Takimoto-Kamimura[1]

[1]TEIJIN PHARMA LIMITED, Teijin Institute for Bio-medical Research, 4-3-2, Asahigaoka, Hino, Tokyo, 191-8512, Japan, [2]Division of Organic Chemistry, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan, E-mail：s.kakuda@teijin.co.jp

The vitamin D receptor (VDR) is a ligand-inducible hormone receptor that mediates 1a,25(OH)2D3 action, determining the calcium and phosphate metabolism, induces potent cell differentiation activity and has immunosuppressive effects. Most analogues of 1a,25(OH)2D3 have been used clinically for some years. However, there is a risk of potential side effects, which limits the use of these substances. (2S)-3-[4-(3-{4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl}pentan-3-yl)-2-methylphenoxy]propane-1,2-diol (YR301) has only strong activity in evaluated four stereoisomers of a novel synthetic non-seco-steroidal vitamin D3 analogue LG902378. To understand the strong activity of YR301, the crystal structure of YR301 with the vitamin D receptor ligand-binding domain (VDR LBD) at 2.0 A was solved and compared with the structure of the rat VDR LBD-1a,25(OH)2D3 complex. YR301 and 1a,25(OH)2D3 share the same position and the diethyl-methyl groups occupy a similar space to CD rings of 1a,25(OH)2D3.YR301 has two characteristic hydroxyl groups which contribute to its potent activity. One is 2'-OH of YR301 which is hydrogen bonding to NE2 of both His 301 and His 393. Another is 2-OH of YR301 which is interacting with OG of Ser233 and NH1of Arg270. Each hydroxyl

group of YR301 exactly corresponds to 25-OH and 1-OH group of 1a,25-(OH)2D3, respectively. The terminal hydroxyl group (3-OH) of YR301 is hydrogen bonded to Arg270 directly and also interacts with OH of Tyr232 and the backbone NH of Asp144 via water molecules indirectly. The substitution of the water molecules might be helpful for the design of more potent compounds.

Keywords: nuclear receptors, vitamin D, structural drug design

P04.15.360

Structural studies of glutathione S-transferase complexed to commonly used chemotherapy agents

Lorien J Parker[1,2], Craig J Morton[1], Mario Lo Bello[3], Michael W Parker[1,2]

[1]St. Vincent's Institute, The ACRF Rational Drug Discovery Facility, 9 Princes St, Fitzroy, Melbourne, Victoria, 3065, Australia, [2]Bio21 Institute, University of Melbourne, [3]Department of Biology University of Rome, Rome, Italy., E-mail：lparker@svi.edu.au

Glutathione S-Transferases (GSTs), phase II detoxification enzymes, primarily function to remove toxic compounds from the cell [1]. They are, however, overexpressed in many cancers and shown to be deleterious to successful chemotherapy treatment by reacting with anti-cancer drugs. GSTs, therefore, have been identified as an attractive target for inhibitor drug design to increase the efficacy of treatment [2]. Drug resistance remains a limiting factor in cancer chemotherapy and thus understanding its mechanism represents an important step in improving cancer treatment. Many reports correlate over-expression of GST and reduced sensitivity to chemotherapy [1]. GSTs are hypothesised to catalyse conjugation of GSH to anti-cancer drugs forming inactive conjugates. This action represents one of a number of possible mechanisms involved in resistance to current chemotherapy treatment. One of the major aims of this work is to determine the 3D structures of these complexes and subsequently pursue structure-based drug design of human GST pi class enzyme (hGSTP1-1) with the aim of discovering effective and specific inhibitors. I have solved the structure of GST with multiple metal based anti-cancer drugs. The structure of the hGSTP1-1/drug complexes reveals a novel ligand binding site. The identification of this site represents a new means by which GST may be contributing to the development of resistance to chemotherapy treatment, in addition to detoxification by GSH conjugation, by sequestering the drugs at this novel site. This information, in conjunction with successful fragment screening, will be used in the design of novel, therapeutic GST inhibitors.

[1] Sheehan, D. et al., (2001) Biochem. J. 360, 1.
[2] Farmer, G. (2004) Nature Rev. Drug. Discov. 3, 547.

Keywords: anticancer drug structural study, enzyme inhibitor drug design, enzyme structure

P04.15.361

Crystal structure of human choline kinase in complex with hemicholinium

Bum-Soo Hong, Wolfram Tempel, Patrick J. Finerty, Abdellah Allali-Hassani, Masoud Vedadi, Matthieu Schapira, Hee-Won Park

Structural Genomics Consortium, University of Toronto, 100-college